There is a clear case for drug treatments to be selected according to the characteristics of an individual patient, in order to improve efficacy and reduce the number and severity of adverse drug reactions 1, 2 . However, such personalization of drug treatments requires the ability to predict how different individuals will respond to a particular drug/dose combination. After initial optimism, there is increasing recognition of the limitations of the pharmacogenomic approach, which does not take account of important environmental influences on drug absorption, distribution, metabolism and excretion [3] [4] [5] . For instance, a major factor underlying inter-individual variation in drug effects is variation in metabolic phenotype, which is influenced not only by genotype but also by environmental factors such as nutritional status, the gut microbiota, age, disease and the co-or pre-administration of other drugs 6, 7 . Thus, although genetic variation is clearly important, it seems unlikely that personalized drug therapy will be enabled for a wide range of major diseases using genomic knowledge alone. Here we describe an alternative and conceptually new 'pharmaco-metabonomic' approach to personalizing drug treatment, which uses a combination of pre-dose metabolite profiling and chemometrics to model and predict the responses of individual subjects. We provide proof-of-principle for this new approach, which is sensitive to both genetic and environmental influences, with a study of paracetamol (acetaminophen) administered to rats. We show pre-dose prediction of an aspect of the urinary drug metabolite profile and an association between predose urinary composition and the extent of liver damage sustained after paracetamol administration.
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1 H nuclear magnetic resonance (NMR) spectroscopy has been widely applied as a metabolite profiling tool for metabonomic studies, as it enables many endogenous metabolites to be quantified rapidly and reproducibly without derivatization or separation [8] [9] [10] [11] . In one of many potential applications, NMR-based metabonomic analysis of post-dose rodent biofluids has been developed as a rapid and non-invasive means of assessing the toxicity of potential drug compounds, and this has involved studying the effects of a variety of model toxins 12 . In one such study, we administered galactosamine hydrochloride (800 mg kg 21 ) to a group of ten rats and found the extent of the induced liver effects to be so variable that the rats could be classified as either 'responders' or 'non-responders'. Searching for the cause of this variation, we performed principal component analysis (PCA) on the NMR spectra of the relevant pre-dose urine samples and observed some discrimination between responder and non-responder groups in terms of their pre-dose metabolite profiles (Fig. 1a) . Although this result was not sufficient to say that galactosamine responder/non-responder behaviour is predictable, it suggested that information on individual responses to xenobiotics might be contained in the metabolite patterns of pre-dose biofluids. We thus conceived the possibility of 'pharmacometabonomics', which we define as 'the prediction of the outcome (for example, efficacy or toxicity) of a drug or xenobiotic intervention in an individual based on a mathematical model of pre-intervention metabolite signatures' .
We also conducted a larger study on the severity of liver damage induced in rats by allyl alcohol (50 mg kg 21 ), and found a weak but statistically significant association between the extent of the induced damage and the pre-dose urinary data (Fig. 1b) , although in this case the discriminating factor was the total pre-dose excretion of organic compounds as estimated by 1 H NMR spectroscopy, rather than the detailed metabolite pattern. However, knowing that the multivariate endogenous metabolite profiles of biofluids reflect inter-subject variation with respect to a multitude of factors such as age, sex, ). Each point represents an individual rat, with colour-coding according to the extent of post-dose liver damage. Red signifies greatest damange, green signifies least damage, mid-damage group excluded. c, Schematic of our pharmaco-metabonomic hypothesis.
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diet, ethnicity and disease [13] [14] [15] [16] [17] , and recognizing that many of the factors that influence the metabolism of drugs would normally operate on endogenous and dietary substances, we decided to test the hypothesis that the pre-dose metabolite profile of an individual animal contains sufficient information to allow the prediction of aspects of drug metabolism and toxicity in that animal without any prior knowledge of the animal's genomic profile (Fig. 1c) . We chose the commonly used analgesic paracetamol (acetaminophen) for this investigation.
We collected pre-and post-dose urine samples from 65 rats given a single toxic-threshold dose of paracetamol (600 mg kg 21 , a treatment that resulted in no mortality or clinical signs), and analysed all of these samples by 1 H NMR spectroscopy (Fig. 2) . The post-dose spectra showed characteristic signals of both endogenous and paracetamol-related metabolites, with the major paracetamol-related metabolites being identified as paracetamol sulphate (S), paracetamol glucuronide (G), the mercapturic acid (MA) derived from paracetamol, and paracetamol (P) itself. Using these spectra in conjunction with the known urinary volumes, we determined the amounts and relative proportions of paracetamol-related metabolites excreted by each animal, and modelled the variation in these data in relation to the multivariate endogenous metabolite profiles obtained from the pre-dose samples. Liver damage of variable severity was identified and quantified by clinical chemistry and histopathology in samples taken at approximately 24 h post-dose, with the extent of the microscopically visible damage being scored in each of five liver lobes and a mean histology score (MHS) derived for each rat (see Supplementary Fig. 1 and Supplementary Tables). The inter-animal variation in MHS was also modelled in relation to the multivariate endogenous metabolite profiles obtained from the pre-dose samples, in an attempt to integrate classical end-point histopathology with a pre-dose metabonomic data set. We then tested the predictive ability of the various models.
The mole ratio of paracetamol glucuronide to paracetamol (G/P) was found to be the most convincingly predicted of the various postdose metabolite quantities. Thus, we built and validated a PLS model (projection to latent structure; see Methods) for predicting, from their pre-dose metabolite profiles, the G/P values obtained post-dose for individual animals (Fig. 3) . The most important factors underlying this model were a positive correlation (r ¼ 0.48) between G/P and the integral of the d5.06-5.14 region of the pre-dose NMR spectra, and negative correlations (r ¼ 20.56 and 20.54) between G/P and the integrals of the d8.98-9.10 and d0.50-0.86 regions of the pre-dose spectra (Fig. 3b) . The integrals for the latter two regions were correlated to one another (r ¼ 0.90), but showed no clear relationship to the integral for the d5.06-5.14 region. Inspection of the pre-dose spectra revealed some small but distinct signals in the d5.06-5.14 region, with the d8.98-9.10 region and much of the d0.50-0.86 region being relatively featureless but positive relative to the zero line.
Our validation (Fig. 3c, d ) confirms that the predictive model for G/P is robust, and the positive correlation between G/P and the d5.06-5.14 region of the pre-dose spectra is consistent with metabolic control. The glucuronide part of paracetamol glucuronide produces a doublet in this region post-dose, and the signals in the d5.06-5.14 region of the pre-dose spectra may arise, correspondingly, from endogenous ether glucuronides. It is logical that G/P would be positively correlated to the pre-existing tendency of each individual rat to form and excrete such ether glucuronides, and the integral for the d5.06-5.14 region could be a good reflection of that tendency, being relatively free of other signals. The significance of the negative correlations between G/P and the specified regions of the pre-dose spectra is not understood, but might reflect some dependency on urinary protein.
Although we did not obtain a fully validated model for predicting post-dose histology, our analysis did show a statistically significant association between the nature of the pre-dose urinary biochemical profile and the post-dose histological outcome. Having assigned each animal to one of three histology classes (described in Table 1 ), PCA was carried out on the pre-dose spectral data (62 animals), with partial separation between histology classes 1 and 3 being found on principal component 2 (PC2) (Fig. 4a) . Furthermore, a weak but statistically significant correlation (r ¼ 20.34; P ¼ 0.007) was found between the PC2 scores and MHS (Fig. 4b) . PCA was also carried out H NMR spectra of pre-dose (a, 248 h to 224 h) and post-dose (b, 0 to þ24 h) urine samples from a rat dosed with paracetamol (600 mg kg 21 ). The inset in a is an expansion of the d1.9-1.0 region, indicating the complexity of the endogenous profile and the richness of the embedded information. 2-OG, 2-oxoglutarate; G, paracetamol glucuronide. on the pre-dose data for classes 1 and 3 only (32 animals), with partial separation of those classes again being observed on PC2 (Fig. 4c) and the statistical significance of that separation being confirmed by a Mann-Whitney U-test (P ¼ 0.002).
The main pre-dose factors underlying the histology class discrimination are the levels of taurine, trimethylamine-N-oxide (TMAO) and betaine (Fig. 4d) . A higher pre-dose level of taurine is associated more with class 1 than with class 3, whereas a higher combined pre-dose level of TMAO and betaine is associated more with class 3 than with class 1. The beneficial relationship found between pre-dose urinary taurine and the extent of paracetamol-induced liver damage is consistent with earlier findings for the degree of liver damage induced by a variety of other liver toxins, and with the protective effect observed when taurine is administered to rats before or soon after a hepatotoxic dose of paracetamol 18, 19 . The significance of the pre-dose level of taurine might lie in its known defensive properties 20 , but urinary taurine might also reflect the availability of inorganic sulphate (to which taurine is metabolically related), which is a precursor of the paracetamol-sulphating agent phosphoadenosine phosphosulfate (PAPS) 21, 22 . The latter interpretation is consistent with our observation that most of the animals with a higher degree of liver necrosis (MHS . 2.5) showed a low proportion of paracetamol sulphate in their post-dose urine. In contrast, a higher pre-dose level of TMAO is associated with more paracetamol-induced liver damage, suggesting that the gut bacteria might have a role in determining the extent of such damage 23, 24 -and the contribution of the gut bacteria to a bayesian probabilistic ('Pachinko') model of metabolism has already been postulated 11 . The occasional pre-dose presence of a significant quantity of betaine, which produces an NMR signal that overlaps that of TMAO, may be a confounding factor and certainly contributed to the abnormal position of one of the class 1 animals on the scores plot shown in Fig. 4c .
Whatever the basis of the observed pre-dose discrimination, our paracetamol study findings identify statistically significant relationships between variation in the pre-dose data and the post-dose variation in histopathology and in the urinary level of a drug metabolite relative to its parent. Thus, the two apparently independent models provide the first demonstration of the concept of pharmaco-metabonomics, in which drug-induced responses in individuals are potentially predictable from their pre-dose metabolite profiles, which serve as biochemical signatures that report simultaneously on multiple factors of relevance to drug metabolism and drug effects.
Looking forward, we propose that this pharmaco-metabonomic approach, which amounts to response-targeted pre-dose phenotyping, might provide the basis of a future population-screening tool for selecting individuals according to their suitability for treatment with particular drugs, drug classes or drug doses. Furthermore, this approach should have certain advantages over methods for drug and dose selection that are dependent on the use of test compounds 25 to characterize particular aspects of an individual's metabolic phenotype. In particular, the pharmaco-metabonomic approach has the potential to provide automatic identification and weighting of multiple response-determining factors. A further inherent benefit of the pharmaco-metabonomic approach is the identification of new biomarkers that are predictive of individual responses.
The main potential application we envisage for pharmaco-metabonomics is with respect to personalized human healthcare, and there is clearly a need for further development and to investigate how well the approach can be transferred from single-strain laboratory animals to human subjects, for whom much greater genetic and environmental variation would be expected. Recent developments in data analysis should assist pharmaco-metabonomic modelling and biomarker identification 26, 27 . Other analytical techniques such as LC-MS and GC-MS might also be used, with the likelihood of detecting a large number of low-concentration metabolites not normally accessible by NMR. Metabolite profiling of fluids other than urine, such as blood and faecal extracts, should also provide additional information. In practice, the success or otherwise of the pharmaco-metabonomic approach would be expected to vary from drug to drug, and would depend on the nature of the challenge posed by each drug, on the response of interest and on the extent to which the relevant response-controlling factors are reported in the pre-dose data. However, in principle, by using this methodology, adverse drug reactions could potentially be avoided and drugs and dose levels could be targeted more effectively according to the metabolic and other characteristics of each individual. We envisage that optimal personalization of drug treatments may eventually involve a variety of response-prediction approaches, including both pharmacometabonomics and pharmacogenomics. However, pharmacometabonomics has an important theoretical advantage over pharmacogenomics in that it can potentially take account of both genomic and environmental factors affecting drug-induced responses. Furthermore, although pharmaco-metabonomics would normally relate to predicting drug-or xenobiotic-induced responses, we envisage that similar methodology could also be applied Figure 4 | Pre-dose discrimination of the degree of liver damage obtained in paracetamol-dosed rats. a, A scores plot from PCA of the pre-dose NMR data. Each point represents a single rat and is colour-coded by its histology class (with increasing severity of damage, class 1 is green, class 2 is blue, class 3 is red; see Table 1 ). b, Plot of mean histology score (MHS) versus the PC2 score obtained from the above PCA, with colour-coding as before. c, A scores plot from PCA of the pre-dose NMR data for rats in histology classes 1 and 3. Each point represents a single rat, with colour-coding as before. d, A loadings plot corresponding to c, showing the variables making the largest contributions to PC2, and the direction of each contribution. Individual 0.04 p.p.m.-wide spectral segments are identified by the chemical shifts at their midpoints, and variables corresponding to particular compounds are identified by name. Tau, taurine; Citr, citrate; Oxog, 2-oxoglutarate; TMAO, trimethylamine-N-oxide; Bet, betaine. '2Tau' indicates doubling of the Tau values. to predicting individual responses to broader medical, dietary, microbiological or physiological challenges.
METHODS
This section relates to the paracetamol study only. Further details are provided in the Supplementary Methods. Animal treatment and sampling. The paracetamol study was performed in accordance with relevant national legislation using 75 male Sprague-Dawley rats (Crl:CD (SD)IGS BR) obtained from Charles River. The rats (approximately seven weeks old) were placed in individual cages in a controlled environment, with free access to water and a commercial feed. Sixty-five animals received, by oesophageal intubation, a single oral dose of paracetamol (600 mg kg
21
) as an aqueous suspension containing methylcellulose (0.5% w/v) and Tween 80 (0.1% w/v). A further ten rats were used as a control group and were orally dosed with vehicle only. Individual pre-dose (248 to 224 h) and post-dose (0-24 h) urine samples were collected into ice-cooled vessels containing 0.5 ml of an aqueous 100 mg ml 21 solution of sodium azide as a preservative. After post-dose urine collection, individual blood samples were collected and centrifuged to recover plasma for clinical chemistry. The rats were then killed using CO 2 and the liver of each animal was examined, weighed and sampled for histopathology. NMR sample preparation, spectral acquisition, processing and construction of data sets. Urine samples were prepared as described in the Supplementary Information. 1 H NMR spectra were acquired (7200 Hz spectral width, 65,536 time domain points, 8 dummy scans, 64 real scans) at 600 MHz, at a nominal 303 K, on a Bruker DRX 600 NMR spectrometer operated by XWINNMR software (both Bruker Biospin) with the 'noesypresat' pulse sequence 28 used to suppress the water signal during a 3-s relaxation delay and during the 0.1-s mixing time. After Fourier transformation with 0.3-Hz line broadening and a single zero-filling, pre-dose spectra were manually phased and baselinecorrected, and the chemical shift scale set by assigning the value of d0 to the signal from the added TSP (sodium 3-trimethylsilyl-[2,2,3,3,-
Each of these processed spectra was then 'data-reduced' using AMIX software (Bruker Biospin), where the spectral regions d . 9.5, d6.1-5.5, d5.0-4.5 and d , 0.5 were discarded before dividing the remainder of each spectrum into sequential segments ('bins') of 0.04 p.p.m. width and obtaining an integral for each segment. These integrals were then normalized to give the same total integral for each data-reduced spectrum. Each bin was initially identified by the chemical shift at its midpoint, but quantities relating to certain compounds were derived by making appropriate bin combinations as described in the Supplementary Information.
Post-dose spectra were processed as above and subsequently with resolution enhancement, in order to determine the amounts and the relative proportions of the paracetamol-related compounds 29, 30 excreted by each animal, by reference to the cluster of N-acetyl signals in the range d2.11-2.22, the TSP signal and the post-dose urinary volume. The amounts excreted were corrected to unit body mass. Clinical chemistry. Blood plasma samples were analysed at 30 8C on an AU600 clinical analyser (Olympus) for a variety of parameters, and univariate statistical analyses were performed. Details and results are provided in the Supplementary Information. Histopathology. For each animal, ten representative samples of the liver (two each from the left, right, left middle, right middle and caudate lobes) were examined, the changes in each lobe scored, a mean histology score (MHS) calculated and a histology class assigned as described in Table 1 . Multivariate modelling. Pirouette (v.2.7 and 3.1, Infometrix) and SIMCA Pþ (v.10.0 and 10.5, Umetrics) software packages were used. After initial investigations, three animals were excluded from all subsequent modelling because of abnormal pre-or post-dose behaviour.
Predictive multivariate modelling was carried out in SIMCA, with a supervised pattern-recognition method (projection to latent structure, PLS) being used to model the co-variation between NMR-derived pre-dose data (X) and selected postdose response variables (Y). Model validation was performed as described in the Supplementary Information. VIP (variable influence on projection) values characterize the relative overall importance of the individual X variables to the model, and the weights for each component of the model reveal the nature of the relationship between each X variable and the predicted quantity, Y.
For predictive modelling of the G/P mole ratio, total area-normalized predose spectral data were used with unit variance variable scaling. An unsupervised pattern recognition method (principal component analysis, PCA) was also used. Histology-coded PCA was performed, using Pirouette, on the pre-dose spectral data normalized to constant total spectral area, with mean-centred variable scaling and with the histology class of each animal assigned as described in 
